Abstract
Secondary bacterial infections, including ventilator-associated pneumonia (VAP), lead to worse clinical outcomes and increased mortality following viral respiratory infections. Critically ill patients with coronavirus disease 2019 (COVID-19) face an elevated risk of VAP, although susceptibility varies widely. Because mechanisms underlying VAP predisposition remained unknown, we assessed lower respiratory tract host immune responses and microbiome dynamics in 36 patients, including 28 COVID-19 patients, 15 of whom developed VAP, and eight critically ill controls. We employed a combination of tracheal aspirate bulk and single cell RNA sequencing (scRNA-seq). Two days before VAP onset, a lower respiratory transcriptional signature of bacterial infection was observed, characterized by increased expression of neutrophil degranulation, toll-like receptor and cytokine signaling pathways. When assessed at an earlier time point following endotracheal intubation, more than two weeks prior to VAP onset, we observed a striking early impairment in antibacterial innate and adaptive immune signaling that markedly differed from COVID-19 patients who did not develop VAP. scRNA-seq further demonstrated suppressed immune signaling across monocytes/macrophages, neutrophils and T cells. While viral load did not differ at an early post-intubation timepoint, impaired SARS-CoV-2 clearance and persistent interferon signaling characterized the patients who later developed VAP. Longitudinal metatranscriptomic analysis revealed disruption of lung microbiome community composition in patients who developed VAP, providing a connection between dysregulated immune signaling and outgrowth of opportunistic pathogens. Together, these findings demonstrate that COVID-19 patients who develop VAP have impaired antibacterial immune defense weeks before secondary infection onset.
One sentence summary COVID-19 patients with secondary bacterial pneumonia have impaired immune signaling and lung microbiome changes weeks before onset.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for the COMET cohort enrollment, sample collection and data analysis derived from: K23HL138461-01A1 (CL), K24HL137013 (PGW), F32 HL151117 (AS), R35 HL140026 (CSC), NIAID U19AI077439 (DJE), Chan Zuckerberg Biohub (AB, JLD). The UCSF IMPACC site was funded by NIAID U19AI077439 (DJE). Funding for enrollment of COMET participants not enrolled in IMPACC and for all sample collection and data analysis derived from K23HL138461-01A1 (CL), K24HL137013 (PGW), F32 HL151117 (AS), R35 HL140026 (CSC), and the Chan Zuckerberg Biohub (AB, JLD). Philanthropic support was provided from Mark and Carrie Casey, Julia and Kevin Hartz, Carl Kawaja and Wendy Holcombe, Eric Keisman and Linda Nevin, Martin and Leesa Romo, Three Sisters Foundation, Diana Wagner and Jerry Yang and Akiko Yamazaki.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Studies were approved by the UCSF Institutional Review Board under protocols 17-24056 and 20-30497
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
+ COMET (COVID-19 Multiphenotyping for Effective Therapies) Consortium members are listed in the Supplementary Appendix
Data Availability
Host gene expression data are available under NCBI GEO accession number GSE168019 for bulk RNA-seq and GSE168018 for scRNA-seq. Raw microbial sequencing alignments are available from NCBI SRA under BioProject PRJNA704082. Code used for differential expression analysis is available at https://github.com/bspeco/VAPinCOVID19.
